N2OFF Closes Merger with MitoCareX Bio

Reuters10-24

N2OFF Closes Merger with MitoCareX Bio

N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-019064), on October 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577535818?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577535818","market":"us","top_or_hot":-1,"title":"N2OFF Closes Merger with MitoCareX Bio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2OFF Closes Merger with MitoCareX Bio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-019064), on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>N2OFF Closes Merger with MitoCareX Bio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nN2OFF Closes Merger with MitoCareX Bio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-24 04:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2OFF Closes Merger with MitoCareX Bio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NITO\">N2OFF, Inc</a>. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-019064), on October 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL1nWB2m:1","article_id":"2577535818","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577535818","pubTimestamp":1761249742,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","BK4539":"次新股","NITO":"N2OFF, Inc","BK4139":"生物科技","SPRC":"SciSparc Ltd.","BK4007":"制药"},"translate_title":"N2OFF完成与MitoCareX Bio的合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRC":0.9,"NITO":0.9},"content_text":"N2OFF Closes Merger with MitoCareX Bio\n    \n\nN2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., a biotech company focused on developing novel therapies for hard-to-treat cancers, including pancreatic and non-small cell lung cancer, by targeting the mitochondrial SLC25 protein family. As a result of the deal, MitoCareX has become a wholly-owned subsidiary of N2OFF. The transaction involved N2OFF purchasing ordinary shares of MitoCareX from SciSparc for $700,000 and issuing common stock to the sellers, representing 40% of N2OFF's fully diluted capital stock. The sellers are also entitled to a share of N2OFF's financing proceeds, capped at $1.6 million over five years, and may receive milestone-based issuances of up to 25% of N2OFF's common stock. The agreement includes a commitment by N2OFF to support MitoCareX's operations for the next two years.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-019064), on October 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577535818","isCrawlerRequest":true}